NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
企業コードNEO
会社名Neogenomics Inc
上場日Dec 10, 2012
最高経営責任者「CEO」Zook (Antony P)
従業員数2200
証券種類Ordinary Share
決算期末Dec 10
本社所在地9490 Neogenomics Way
都市FORT MYERS
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号33912
電話番号12397680600
ウェブサイトhttps://neogenomics.com/
企業コードNEO
上場日Dec 10, 2012
最高経営責任者「CEO」Zook (Antony P)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし